Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis

• Published in: European journal of medicinal chemistry Vol. 263; pp. 115968 - 115989
• Main Authors: Liu, Zhikun, Cai, Jinyuan, Jiang, Guiyang, Wang, Meng, Wu, Chuang, Su, Kangning, Hu, Weiwei, Huang, Yaxian, Yu, Chunhao, Huang, Xiaochao, Cao, Guoxiu, Wang, Hengshan
• Format: Journal Article
• Language: English
• Published: ISSY-LES-MOULINEAUX Elsevier 05.01.2024
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; Cell Line, Tumor; Chemistry, Medicinal; Cisplatin - pharmacology; Colonic Neoplasms - drug therapy; Drug Resistance, Neoplasm; Ferroptosis; Humans; Life Sciences & Biomedicine; Oxaliplatin - pharmacology; Pharmacology & Pharmacy; Platinum - pharmacology; Science & Technology; Multi-functional antineoplastic; CELLS; IN-VITRO; CISPLATIN; Ferroptosis inducer; PRODRUGS; AGENTS; Platinum(IV) complexes; DERIVATIVES; Overcoming oxaliplatin resistance; HYBRIDS
• ISSN: 0223-5234; 1768-3254; 1768-3254
• DOI: 10.1016/j.ejmech.2023.115968

Platinum-based chemotherapeutics are widely used for cancer treatment but are frequently limited because of dosage-dependent side effects and drug resistance. To attenuate these drawbacks, a series of novel platinum(IV) prodrugs (15a-18c) were synthesized and evaluated for anti-cancer activity. Among them, 17a demonstrated superior anti-proliferative activity compared with oxaliplatin (OXA) in the cisplatin-resistant lung cancer cell line A549/CDDP and OXA-resistant colon cancer cell line HCT-116/OXA but showed a lower cytotoxic effect toward human normal cell lines HUVEC and L02. Mechanistic investigations suggested that 17a efficiently enhanced intracellular platinum accumulation, induced DNA damage, disturbed the homeostasis of intracellular reactive oxygen molecules and mitochondrial membrane potential, and thereby activated the mitochondrion-dependent apoptosis pathway. Moreover, 17a significantly induced ferroptosis in HCT-116/OXA via triggering the accumulation of lipid peroxides, disrupting iron homeostasis, and inhibiting solute carrier family 7 member 11 and glutathione peroxidase 4 axial pathway transduction by inhibiting the expression of the phosphorylated signal transducer and activator of transcription 3 and nuclear factor erythroid 2-related factor 2. Moreover, 17a exerted remarkable in vivo antitumor efficacy in the HCT-116/OXA xenograft models but showed attenuated toxicity. These results indicated that these novel platinum(IV) complexes provided an alternative strategy to develop novel platinum-based antineoplastic agents for cancer treatment.